Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Subsidiary NRLBH, BioVentive Ink Marketing Deal

NEW YORK (GenomeWeb) – Atossa Genetics announced today that its subsidiary, the National Reference Laboratory for Breast Health, and BioVentive have reached a deal to market and promote NRLBH's services.

NRLBH is a CLIA-registered laboratory based in Seattle that offers anatomic and clinical pathology services and molecular-based testing. BioVentive provides sales and marketing services to healthcare companies.

In a statement, Atossa President and CEO Steven Quay said that BioVentive's sales force is "highly regarded by the medical community," and that he anticipates the company will play "a vital role as the NRLBH develops and commercializes its testing services."

Atossa develops tests and other medical devices, as well as laboratory services and therapeutics aimed at breast cancer. Its lab services are being developed by NRLBH. BioVentive has a sales force of 85 who will offer NRLBH's services throughout the US, Quay added.

Financial and other terms of the deal were not disclosed.

Last week Atossa announced it submitted additional information to the US Food and Drug Administration related to its 510(k) submission for the ForeCYTE Breast Aspirator.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.